Sickle cell disease (SCD) is a group of genetic blood disorders. A person inherits SCD from their parents when they inherit two copies of the sickle cell gene, one from each parent. This ...

Sickle Cell Disease Market Size Was Valued at USD 2.40 Billion in 2023, and is Projected to Reach USD 12.38 Billion by 2032, ...

BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...

Editas Medicine announced proof-of-concept data for a gene-editing approach for sickle cell disease that doesn't need a stem ...

The mother of a teenager with sickle cell disease said medical treatment for the genetic blood disorder was a "postcode ...

Participants at the launch of National Sickle Cell Disease Strategy and National Vaccine Policy The Ministry Of Health has ...

Beam Therapeutics' early clinical data shows promising results for sickle cell disease treatment using CRISPR gene editing tool. One patient died ...

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...

The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of ...

A patient with sickle cell disease died while participating in a clinical trial of a CRISPR-based treatment from Beam Therapeutics, threatening to overshadow early signals of effective gene editing.

Ghana on Tuesday unveiled a National Sickle Cell Disease (SCD) Strategy aimed at improving both preventive and treatment services for the condition.

This case study is an example of how the MHRA is benefiting from patients providing their lived experience for the pre-authorisation stage of the ...